TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05609825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3875383
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3875383
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3875383
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3875383
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT06116981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Induction Magnetic Field Therapy
Description: High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Treatment
Description: Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
Study: NCT04740580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: The placebo arm will supplement Alanine
Study: NCT04893512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orally Suspension of CoV2-OGEN1
Description: CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
Study: NCT06059456

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Intramuscular or subcutaneous administration

Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: Intramuscular or subcutaneous administration
Study: NCT05852730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel
Study: NCT06178588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study: NCT06495515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib，Toremifen
Description: 1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs).
Study: NCT06178588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05341882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Support
Description: As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
Study: NCT06230718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Description: mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Description: rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition- placebo
Description: Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
Study: NCT05919316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinophototherapy
Description: Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
Study: NCT05852730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other (e.g., promethazine, meclizine)
Description: Subjects will self-administer other medications as available.
Study: NCT05715944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 1222
Description: Vaccine
Study: NCT06178588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV
Study: NCT05385627

Intervention type: PROCEDURE
Intervention: Ankle block
Description: Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
Study: NCT04298190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy for Adolescents (DBT-A)
Description: 16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
Study: NCT05121831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001Dose 1
Description: Dose level 1 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001Dose 1
Description: Dose level 1 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 2
Description: Dose level 2 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 2
Description: Dose level 2 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 3
Description: Dose level 3 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 3
Description: Dose level 3 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 4
Description: Dose level 4 of DGX-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD dose panel of DGX-001
Description: Dose levels confirmed through SAD and MAD
Study: NCT05307341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
Study: NCT05572788

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EUS-guided fine needle aspiration of pancreatic cysts
Description: Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle aspiration of pancreatic cysts
Description: Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
Study: NCT05690672

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Delirium Screening
Description: Either 3D-CAM or 4AT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Delirium Screening
Description: Either 3D-CAM or 4AT
Study: NCT05860998

Intervention type: DIAGNOSTIC_TEST
Intervention: Presence of Toxoplasma gondii IgG Antibodies
Description: Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Presence of Toxoplasma gondii IgG Antibodies
Description: Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
Study: NCT05060172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife MFM-Pro
Description: Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data.
Study: NCT04857788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pandah Application smartphone only
Description: Patients will have an application on their smartphone to help them do their homework
Study: NCT05389384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive shoulder exoskeleton
Description: Participants complete overhead working task with support of exo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive shoulder exoskeleton
Description: Participants complete overhead working task with support of exo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: Participants complete a fatiguing protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: Participants complete a fatiguing protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No exoskeleton support
Description: Exoskeleton is worn, but no support provided

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No exoskeleton support
Description: Exoskeleton is worn, but no support provided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No peripheral fatiguing protocol
Description: Participants complete no fatiguing protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No peripheral fatiguing protocol
Description: Participants complete no fatiguing protocol
Study: NCT04687007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-ALD
Description: At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Description: At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
Study: NCT06173661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fremanezumab
Description: The intervention will be active medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will be placebo injection.
Study: NCT04977973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided programme on body image
Description: Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided programme on cooperation
Description: Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program.
Study: NCT06357884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Callus debridement
Description: Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
Study: NCT05127291

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-task
Description: In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task
Description: In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
Study: NCT05923892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071
Description: There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
Study: NCT04980469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitex negundo + Zingiber officinale
Description: 200 mg/ Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MCC)
Description: 200 mg/ Capsule
Study: NCT05207748

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone mineral density
Description: Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone mineral density
Description: Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
Study: NCT05593354

Intervention type: DEVICE
Intervention: Micropulse Transscleral laser therapy
Description: Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
Study: NCT05854537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine ganglion block using bupivacaine: xylocaine
Description: Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine ganglion block using normal saline
Description: Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
Study: NCT05462106

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose A
Description: Administration of Dose A of ACI-24.060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose B
Description: Administration of Dose B of ACI-24.060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose C
Description: Administration of Dose C of ACI-24.060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose D
Description: Administration of Dose D of ACI-24.060
Study: NCT04924010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and Mindfulness
Description: To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
Study: NCT05919316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray
Description: 50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
Study: NCT05935241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPATH
Description: The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
Study: NCT05318274

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiotherapy
Description: Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
Study: NCT05462106

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo